Skip to main content
Premium Trial:

Request an Annual Quote

Decode’s Genotyping Business Drives Double-Digit Growth in Q3 Revenues

NEW YORK (GenomeWeb News) - Decode Genetics yesterday said third-quarter revenues rose 27 percent while R&D spending was steady and net loss widened by 3 percent.
 
Total receipts for the three months ended Sept. 30 climbed to $10.9 million from $8.6 million year over year — an increase that the company attributed to its growing genotyping business.
 
R&D spending ticked down to $14.1 million from $14.2 million year over year.
 
Net loss increased to $24.3 million from $23.6 million in the year-ago period.
 
Decode said it had around $118.6 million in cash, cash equivalents, and investments as of Sept. 30.
 
Company CEO Kari Stefansson said Decode has continued to expand its DNA-based risk predisposition tests by launching an assay for myocardial infarction. Decode also plans to launch tests for other conditions, including one for glaucoma, in the near future.

The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.